Latest news
Replimune to ride wave of physician support to launch advanced melanoma therapy - BioSpaceBioSpace · Fri, 07 Aug 2026 14:28:05 GMTThird time’s the charm for Replimune as melanoma drug earns FDA greenlight - BioSpaceBioSpace · Thu, 06 Aug 2026 22:18:12 GMTChaotic adcomms threaten to derail FDA’s bid to renew trust after Makary, Prasad - BioSpaceBioSpace · Wed, 05 Aug 2026 13:39:37 GMTRumors of biggest pharma merger ever drop amid Q2 earnings, contentious FDA adcomms - BioSpaceBioSpace · Wed, 05 Aug 2026 11:21:15 GMTReplimune overcomes ‘messy data’ to secure positive adcomm vote for melanoma therapy - BioSpaceBioSpace · Thu, 30 Jul 2026 07:00:00 GMTCapricor and Replimune prep for FDA adcomms, Q2 earnings roll on, Sarepta’s new leader, more - BioSpaceBioSpace · Wed, 29 Jul 2026 07:00:00 GMTFDA says Replimune’s melanoma data package is ‘not interpretable,’ setting up tough adcomm - BioSpaceBioSpace · Tue, 28 Jul 2026 07:00:00 GMTFDA has recommitted to adcomms—but to what end? - BioSpaceBioSpace · Mon, 27 Jul 2026 07:00:00 GMT